Associations among plasma concentrations of regorafenib and its metabolites, adverse events, and ABCG2 polymorphisms in patients with metastatic colorectal cancers.
Kazuo KobayashiErika SugiyamaEiji ShinozakiTakeru WakatsukiMasataka TajimaHiyori KidokoroTakeshi AoyamaYasuhiro NakanoKazuyoshi KawakamiKoki HashimotoMitsukuni SuenagaTakashi IchimuraMariko OguraKeisho ChinIzuma NakayamaAkira OokiDaisuke TakahariWataru SuzukiTakashi YokokawaYuichi MinowaTomoko HiraokaKenichi SuzukiHitoshi SatoToshihiro HamaKensei YamaguchiPublished in: Cancer chemotherapy and pharmacology (2021)
This study showed that the Ctrough of regorafenib was associated with bilirubin increase, and also clarified for the first time that the Ctrough of M5 was significantly correlated with hypertension and severe rash.